Agendia announces companion diagnostics agreement with Daiichi Sankyo - Gilde Healthcare

Agendia announces companion diagnostics agreement with Daiichi Sankyo

25. April 2014

IRVINE, CA and AMSTERDAM – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

“This exciting early stage research collaboration represents a potential new area for additional commercialization and expansion of Agendia’s platform technology,” said David Macdonald, Agendia’s President and CEO. “We are very pleased to apply our expertise to assist with the potentially groundbreaking work being done by Daiichi Sankyo.”

Macdonald noted that Agendia has a long history of providing clinically valuable information about gene expression in oncology. “With this new agreement, our molecular diagnostics technology will now be applied to additional areas of oncology research,” he said.

As part of the agreement between Agendia and Daiichi Sankyo, Agendia technology will be used to assess patient samples. Terms and other aspects of the agreement were not disclosed.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. For more information, visit www.daiichisankyo.com.

About Agendia (www.agendia.com)

Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint, as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, and TargetPrint®, an ER/PR/HER2 expression assay. MammaPrint is the only breast cancer recurrence assay back by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led...
11. Januar 2022

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens,...
21. Dezember 2021

Philips acquires Gilde portfolio company Vesper Medical to further expand its image-guided therapy devices portfolio

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices....
14. Dezember 2021